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bleomycin; fibroblasts; proteoglycans IDIOPATHIC PULMONARY FIBROSIS (IPF) is characterized by abnormal deposition of ECM proteins, including proteoglycans (PGs), leading to loss of normal lung structure and function (4, 35, 46) . PGs are key components of the ECM of the lung (35) and are characterized by the presence of one or multiple glycosaminoglycan (GAG) side chains covalently linked to a core protein. PGs provide the tissue with many of its characteristic physicochemical properties and control cellular activity (7, 15) . Evidence to date suggests that many of these biological interactions are properties of the GAG side chains, which play important roles in growth factor signaling, cellular differentiation, morphogenesis, and pathophysiology (17, 19, 21, 28, 36 -38, 41) . We have previously demonstrated that GAGs were important determinants of lung biomechanical properties (1) and that the antiproliferative and/or proapoptotic effect of decorin PG is due to its GAG side chain (9) .
The lung tissue contains four structurally different GAGs: heparan sulfate (HS)/heparin, chondroitin/dermatan sulfate (CS/DS), keratan sulfate (KS), and hyaluronic acid (HA). HA, the most abundant nonsulfated GAG in the lung ECM, binds specifically with large CS-containing PGs, forming macromolecular aggregates in the interstitial matrix that influence tissue hydration (35, 36) . CS/DS chains consist of repeating disaccharides of D-glucuronic acid (GlcUA) and N-acetyl-D-galactosamine (GalNAc) and are modified by presence of sulfate groups at C-2 position of GlcUA/L-iduronic acid and/or C-4 and/or C-6 positions of GalNAc to generate a range of structural units. In DS, many of the GlcUA residues become epimerized at C-5 to yield L-iduronic acid (21, 36) .
Although studies have shown fibrotic lesions to contain increased PGs, these are related to PG core protein only (4, 11, (43) (44) (45) . Changes in PG core protein alone provide only a partial assessment of changes in PG synthesis and are inadequate as it reveals only core protein number and not changes in GAG content and/or fine structure. This point is vital given the potential impact of GAG sulfation and disaccharide composition for cytokine-PG interactions in normal development and function and for responses to tissue damage and infection (17, 32, 34, 47) . In this study, we have directly examined the accumulation and precise distribution of CS-GAG chains as well as disaccharide composition and sulfation of CS/DS in normal and fibrotic lung. As there are no data on the mechanistic link underlying the increased expression of GAGs in fibrosis, we also investigated the expression of ␤1,3-glucuronosyltransferase I (GlcAT-I), the enzyme that controls CS/DS GAG chain synthesis (3, 42) , in a rat model of bleomycin (BLM)-induced lung fibrosis. We extended our observations to pathology specimens obtained from human patients with documented IPF and control subjects. Our results demonstrate that the disaccharide composition and sulfation profile of CS/DS chains increases markedly with development of pulmonary fibrosis in rats. Most notably, the data presented herein show that CS-GAG chains and the GlcAT-I protein are increased in patients with IPF compared with normal lung.
METHODS
Patients. Studies were carried out in patients with IPF, and the diagnosis of IPF was in accordance with the criteria of the 2002 American Thoracic Society/European Respiratory Society consensus report (2, 24) . Tissue samples from patients undergoing resection for lung cancer were included as controls, with the tissue being sampled in areas distant from the tumor (24) . All procedures for consent and data collection were reviewed and approved by an institutional ethics committee of McMaster University (for details, see the data supplement online at the AJP-Lung Cellular and Molecular Physiology web site).
BLM-induced pulmonary fibrosis. Pulmonary fibrosis was induced in male Sprague-Dawley rats (weight: 275-350 g) by a single intratracheal instillation of 1.5 units of BLM (11, 43) in 0.3 ml of saline. Control rats received an equal volume of saline only. At 3, 5, 7, 14, and 28 days after BLM administration, animals were euthanized by an overdose of sodium pentobarbital (60 mg/kg) and severing of the inferior vena cava. Cell-free lung lavage fluid and lungs were analyzed for disaccharide composition and sulfation of GAGs as described in the online supplement. Four to six animals were studied in each group. All animals received humane care in compliance with the Guide to the Care and Use of Experimental Animals formulated by the Canadian Council of Animal Care, and procedures were reviewed and approved by an institutional animal ethics committee of McGill University.
Primary rat lung fibroblast culture and treatments. Isolation, culture, phenotypic characterization, and maintenance of rat lung fibroblasts were done as previously reported (44) . Experiments were performed with cells obtained from saline-instilled control (SLF) or BLM-instilled fibrotic (BLF) lungs. Fibroblasts were grown to confluence and then serum-deprived (0.1% FBS) for 24 h before stimulation with transforming growth factor-␤ 1 (TGF-␤1; 5 ng/ml) for 6, 18, 24, and 48 h or with anti-TGF-␤ antibody (10 g/ml) or control IgG for 18 or 48 h. The concentration of TGF-␤1 or anti-TGF-␤ antibody used in the present study was based on previous studies on PG production using fibroblasts derived from normal and fibrotic rat lung (44) . In other experiments, normal lung fibroblasts (SLF) were preincubated for 2 h with varying concentrations (0, 10, 20, 25, and 50 M) of TGF-␤ type I receptor/activin receptor-like kinase 5 (ALK5) inhibitor SB-431542 or p38 MAPK inhibitor SB-203580 before treatment with TGF-␤1 for 18 or 48 h. At the end of the experimental period, the expression levels of GlcAT-I were determined by real-time quantitative RT-PCR (QRT-PCR), and GAG content was measured by dye binding assay as described below. All experiments were carried out with fibroblasts between the 4th and 6th passages, and cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air.
RNA extraction and mRNA quantification. RNA extraction from fibroblast monolayers and lung tissues and quantification of mRNA by QRT-PCR expression were performed (see online supplement).
Immunohistochemical localization of GAGs and GlcAT-I protein.
Immunostaining of GAGs and GlcAT-I was performed with antibodies specific to chondroitin-4-sulfate (C-4-S; 1:750 dilution), chondroitin-6-sulfate (C-6-S; 1:250 dilution), or CS types A and C (specific for the GAG portion of native CS-PG; 1:200 dilution) or anti-GlcAT-I (1:250 dilution). An anti-GlcAT-I antibody was generated in rabbits against the conserved peptide 301 CTRVLWHTRTEKPK 315 in the motif IV of ␤1,3-glucuronosyltransferases following standard protocols. Antibody purity was assessed by SDS-PAGE and has previously been verified to react with rat protein (42) . Negative controls were processed similarly, except incubation with isotype-matched control antibody was substituted for primary antibody (same concentration as the test antibody; see online supplement for details).
FACE. Analyses of disaccharide composition of hyaluronan and CS/DS were performed using fluorophore-assisted carbohydrate electrophoresis (FACE) (5) . Briefly, proteinase K-digested lung or fibroblast cultures were assayed for the concentration of GAGs by the 1,9-dimethylmethylene blue assay (14) , and then equal amounts of GAGs were subjected to hyaluronidase and chondroitinase ABC [100 milliunits (mU)/ml each] to generate disaccharides from hyaluronan and CS/DS for 4 h at 37°C. Samples were dried, derivatized with 2-aminoacridone, fluorotagged, and electrophoresed on a mono composition gel (see online supplement for details).
SDS-PAGE and immunoblotting of GlcAT-I.
Homogenates from fibroblast cultures or lungs were prepared by lysing cells or homogenizing lungs with RIPA buffer (1ϫ phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, and 100 mM sodium orthovanadate). After centrifugation at 3,000 g, the supernatant was assayed for protein concentration by bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL). Immunoblotting for GlcAT-I was performed as described previously (42) . GAPDH or ␤-actin was used to check for equal protein loading in immunoblot analysis.
Quantification of GAG disaccharides and immunoblots. Densitometry analysis of GlcAT-I blots and FACE gels was accomplished with image analyzer software (FluorChem; Alpha Innotech, San Leandro, CA), which measures the sum of all pixel values after background correction. The mean values of three to six experiments are presented.
Statistical analysis. All data are presented as means Ϯ SE of three to six observations. Comparison between normal and fibrotic lung fibroblasts was performed by Student's t-test for paired or unpaired data, as appropriate. For comparison among multiple groups, one-way ANOVA followed by Tukey post hoc correction test was used. Statistical analyses were performed using GraphPad Prism software (version 4.0).
RESULTS

BLM-induced pulmonary fibrosis results in increased deposition and alterations in tissue distribution of CS chains.
Immunostaining using sulfation-specific antibodies revealed increased expression of C-4-S (Fig. 1B) , C-6-S (Fig. 1E) , and CS types A and C (Fig. 1H ) in BLM lungs (Fig. 1, B , E, and H) compared with controls ( Fig. 1, A, D, and G) , and the distribution of these GAGs was more diffuse and extensive in fibrotic lungs. Control lungs showed only minimal staining for CS-GAGs around airways, blood vessels, and in the alveolar wall. The more extensive deposition of CS-GAG chains present at 14 days after BLM injury is consistent with the high levels of CS disaccharides expression that were detected at this time point by FACE (Fig. 2 ) and biochemical analyses (Fig. 3) . Negative controls (Fig. 1, C, F , and I) failed to show immunostaining for CS-GAG chains.
BLM-induced pulmonary fibrosis results in increases in CS/DS sulfation patterns in lungs.
The internal unsaturated disaccharide analysis of hyaluronan and CS/DS chains indicated the presence of unsaturated ⌬DiHA disaccharide from hyaluronan and unsaturated monosulfated (⌬Di4S and ⌬Di6S) and unsulfated (⌬Di0S) disaccharides from CS/DS chains in control lungs (Fig. 2) . Although it is possible that small amounts of disulfated and higher sulfated products might have been present in the GAG chains, we could detect no such units under our assay conditions. FACE analysis (Fig. 2 ) also indicated that 4-sulfated disaccharides were predominant in adult rat lungs. Interestingly, fibrotic lungs showed a time-dependent increase in the content of CS/DS and hyaluronan disaccharides. Figure 2B revealed an ϳ5-fold increase in ⌬DiHA at day 7 after fibrosis induction, but this increase decreased on days 14 and 28, although the expression of ⌬DiHA remained elevated over controls. There was no significant difference in the content of ⌬Di0S between normal and fibrotic lungs (Fig. 2C) . Compared with controls, the ⌬Di6S content increased nearly 2-fold at 7 days and 3-fold at 14 days after BLM and was still higher at day 28 post-BLM instillation (Fig. 2D) . The ⌬Di4S content increased by 2-fold on day 7, peaked on day 14 (a 3-fold increase compared with controls), and remained elevated at day 28 after BLM-induced fibrosis (Fig. 2E) .
Quantitative analyses of GAGs in normal and fibrotic lungs. To support our FACE results and immunohistochemical staining of GAG chains, we also measured the concentration of CS/DS GAGs in normal and fibrotic rat lungs. Our biochemical analyses demonstrated increased amounts of total sulfated GAGs (expressed in micrograms per 0.1 g dry weight of lung tissue; Fig. 3A ) and CS/DS (Fig. 3B ) contents in fibrotic lungs compared with control lungs. These data indicated that biochemical measurements of changes in sulfation patterns and CS/DS contents were similar to immunohistochemical staining and FACE analyses of GAG chains in fibrotic lungs.
Increases in hyaluronan and CS disaccharides in the lung lavage fluid of rats with BLM-induced pulmonary fibrosis.
Next, we explored the possibility that measurements of changes in HA and CS/DS disaccharides in bronchoalveolar lavage fluid (BALF) could be considered as "markers," providing a new approach to monitor PG metabolism during ECM remodeling in fibrosis. Cell-free BALF from both normal and fibrotic rats showed the presence of ⌬DiHA, ⌬Di4S, and ⌬Di6S in BALF (Fig. 4) . HA disaccharides were detectable 3 days after BLM (3.6-fold; Fig. 4B ), which increased further in the BLM rat at 5 days (ϳ7-fold) and were even more elevated by day 7 (ϳ20-fold). HA disaccharides subsequently decreased after 14 days, reaching control levels at day 28 ( Fig. 4B) . The content of 4-sulfated disaccharide reached a maximum increase of 3-fold at 14 days and remained elevated at the same level 28 days after BLM injury (Fig. 4D ). Whereas the 6-sulfated disaccharide content showed a propensity to increase in BLM rats (Fig. 4C ), no expression of ⌬Di0S was present in the BALF under our assay conditions.
HA and CS/DS disaccharides are elevated in fibrotic lung fibroblasts. Fibroblasts, the prime source of ECM proteins, are considered key mediators of wound repair and abnormal deposition of ECM in tissue fibrosis (10, 25) . To test the hypothesis that fibroblasts may be involved in the pathological accumulation of GAGs, we compared the expression of GAG chains by fibroblasts isolated 14 days after SLF and BLF rat lung. Similar results were obtained for both the cell layer and , chondroitin-6-sulfate (C-6-S; D and E), and CS types A and C (CS-A&C; G and H). Lung from control rats at 14 days showed normal alveolar architecture with minimal staining of CS chains around airways, blood vessels, and alveolar walls, whereas an intense immunostaining was observed in the areas of lung injury and developing fibrosis of rats at 14 days after bleomycin (BLM) administration. The dark brown color is indicative of strong CS expression and deposition. C, F, and I are negative controls from BLM lungs stained with isotype-matched control antibody. Original magnification, ϫ100.
medium compartments with regard to disaccharide composition and sulfation patterns of GAGs; consequently, we present the data obtained from the cell layer.
The densitometry analysis in Fig. 5 demonstrated that BLF increased the expression of ⌬DiHA between 2.5-and 3-fold of the control (Fig. 5B ). BLF also increased ⌬Di6S (Fig. 5D ) and ⌬Di4S ( Fig. 5E ) expression to 2-and 4-fold of the control, respectively, but had no significant effect on the expression of ⌬Di0S (Fig. 5C ). Thus our in vitro findings, consistent with the observation on the in vivo expression of HA and CS/DS disaccharides, support the involvement of fibroblast activity in mediating the increased expression of GAGs in pulmonary fibrosis.
TGF-␤ 1 induces lung fibroblast HA and CS/DS disaccharide expression. As fibrotic lung fibroblasts expressed high levels of TGF-␤ 1 protein (44), we hypothesized that fibrogenic microenvironmental factors, such as TGF-␤ 1 , may stimulate HA and CS/DS chain expression in BLF. To examine this possibility, we cultured SLF to 80% confluence and then serum-starved for 24 h. After serum starvation, cells were treated with serum-free medium or TGF-␤ 1 (5 ng/ml) for 48 h. The concentration of TGF-␤ 1 and the time point used in this study were selected based on previous reports (44) . As illustrated in Fig. 6 , TGF-␤ 1 induced significant expression of HA disaccharides (a 3-fold increase compared with controls; P Ͻ 0.02) in normal lung fibroblasts (Fig. 6B) . TGF-␤ 1 treatment was also accompanied by an increase in both 4- (Fig. 6E ) and 6-sulfation (Fig. 6D ) of 2.5-and 10-fold, respectively. C-0-S disaccharide was unaffected by TGF-␤ 1 (Fig. 6C) , consistent with the observation that C-0-S levels were not influenced by BLM-induced fibrosis (Fig. 2C) . These findings suggest that exogenous cytokine exposure can cause similar alterations in HA and CS/DS disaccharide composition (Fig. 6A ) in lung fibroblasts as those observed in fibrotic lungs.
Increase in HA and CS/DS disaccharide expression in fibrotic lung fibroblasts can be reversed by neutralizing antibody to TGF-␤ 1 . Further studies were undertaken to determine whether HA and CS/DS disaccharides upregulation in BLF could be inhibited by treating cells with neutralizing anti-TGF-␤ 1 antibody. In these experiments, BLF were incubated with control medium or anti-TGF-␤ 1 antibody (10 g/ml) for 48 h, and the disaccharide levels of HA and CS/DS (Fig. 7A) were then assessed. Incubation of BLF with anti-TGF-␤ 1 antibody decreased HA disaccharide levels compared with control groups (Fig. 7B ). Both C-4-S (Fig. 7E ) and C-6-S (Fig.  7D ) disaccharides in the presence of anti-TGF-␤ 1 antibody were also markedly downregulated compared with the control. Similar experiments with SLF revealed that anti-TGF-␤ 1 antibody was able to downregulate endogenous HA and CS/DS disaccharides ( Fig. 6 ) We further treated fibroblasts with nonimmunizing antibody that had no effect on cellular HA and CS/DS disaccharide expression in both normal and fibrotic lung fibroblasts (data not shown). These results indicate that TGF-␤ 1 is involved in the physiological and pathological GAG expression. Fig. 2 . Fluorophore-assisted carbohydrate electrophoresis (FACE) analyses (A) and densitometry quantitation (B-E) of hyaluronan (HA) and chondroitin/ dermatan sulfate (CS/DS) disaccharides produced from proteinase K-digested control and fibrotic lung tissues by hyaluronidase and chondroitinase ABC digestion. Enzyme-digested products were fluorotagged and separated by FACE to identify and quantitate ⌬disaccharides. Disaccharides were identified by coelectrophoresis with standards. Densitometry analysis of disaccharides was performed with image analyzer software (see METHODS) . Values are means Ϯ SE of 5 animals and expressed in arbitrary densitometry units. One-way ANOVA with post hoc Tukey test was used for statistical analysis of the data. ⌬DiHA, HA-unsaturated disaccharide; ⌬Di0S, nonsulfated chondroitin-unsaturated disaccharide; ⌬Di4S, chondroitin-4-sulfated unsaturated disaccharide; ⌬Di6S, chondroitin-6-sulfated unsaturated disaccharide.
Fibrotic rat lungs display increased expression of GlcAT-I protein.
To mechanistically investigate why fibrotic lungs have increased expression of CS-GAGs, we examined lung tissues for expression of GlcAT-I, a key regulator and rate-limiting enzyme for the synthesis of GAG chains. There are 2 other isoforms, GlcAT-P and GlcAT-S, described in humans and in rats that catalyze reactions similar to the I isoform (the transfer of glucuronic acid) and are also involved in the biosynthesis of the carbohydrate epitope HNK-1 but are unrelated to GAG synthesis. There are several other isoforms of UDP-glucuronosyltransferase in humans and rats, but these enzymes are solely involved in the detoxication of xenobiotics, including drugs and environmental compounds. These latter isoforms are localized in the endoplasmic reticulum membrane and are not involved in GAG synthesis. In this study, we have analyzed the expression of GlcAT-I, which is mainly involved in the biosynthesis of the GAG-protein linkage region of PGs, using specific antibody and primers. Increased immunostaining for GlcAT-I protein was observed in fibrotic lungs (Fig. 8B ) compared with normal lungs (Fig. 8A) , which is indicative of fibrotic potential. Negative controls showed no immunoreactivity for GlcAT-I protein (Fig. 8C) . Double-labeling studies showed colocalization of GlcAT-I protein with Golgi (Supplemental Fig. S1 ). Consistently, immunoblotting (Fig. 8D) and densitometry (Fig. 8E ) of lung homogenates prepared from BLM rats showed an immunoreactive band of increased intensity by day 7 post-BLM (ϳ2-fold over controls), which was further elevated at 14 (ϳ4-fold over baseline) and 28 (3.5-fold over baseline) days after BLM injury.
BLF demonstrate increased GlcAT-I gene and protein expression. Next, we used the in vitro fibroblast culture model to obtain specific information about the regulation of PG-GAG synthetic genes in fibrosis as well as in response to TGF-␤ 1 treatment. Results in Fig. 5 demonstrated an increase in the amount of CS-GAGs produced by fibrotic lung fibroblasts compared with normal fibroblasts. To determine whether increased GAG levels in BLF were due to increased production of GlcAT-I, we compared the expression of GlcAT-I protein (Fig. 8F ) in SLF and BLF. Densitometry results (Fig. 8G) showed that GlcAT-I protein was significantly (P Ͻ 0.005) upregulated (ϳ3-fold increase compared with SLF) in BLF. To determine whether increased GlcAT-I protein in BLF were due to enhanced gene expression of GlcAT-I, we analyzed GlcAT-I mRNA levels. Consistent with the protein data, BLF had relatively higher levels of GlcAT-I mRNA expression compared with normal cells (Fig. 8H ). These observations indicate that GlcAT-I may be involved in increased expression of GAGs in fibrotic lungs. In addition to augmenting GlcAT-I mRNA and protein expression, BLF also showed a 15-fold elevation of versican mRNA (Fig. 8I ) expression over normal cells, which is in agreement with our earlier report on increased versican protein expression by BLF (44) . Together, these findings demonstrate that BLF exhibit a fibrotic phenotype as demonstrated by the fibrotic lung in vivo.
TGF-␤ 1 induces GlcAT-I expression in rat lung fibroblasts. We (44) reported earlier that BLF produced higher levels of TGF-␤ 1 compared with normal fibroblasts. We therefore determined whether TGF-␤ 1 enhances PG-GAG production in fibroblasts by inducing GlcAT-I and versican core protein expression. To determine the time course of the change in GlcAT-I expression with TGF-␤ 1 treatment, we studied the kinetics of GlcAT-I mRNA expression levels in normal lung fibroblasts following a 6-, 18-, and 24-h treatment with TGF-␤ 1 (5 ng/ml). As measured by QRT-PCR, our results showed that the levels of GlcAT-I expression were greatly increased in a time-dependent manner on treatment of fibroblasts with TGF-␤ 1 in vitro (Fig. 9A) . The levels of GlcAT-I mRNA in TGF-␤ 1 -treated fibroblasts started to increase at 6 h and were ϳ3-fold higher at 18 and 24 h than those in cells without TGF-␤ 1 . We next assessed whether TGF-␤ 1 treatment also enhanced GlcAT-I protein expression (Fig. 9B) . Consistent with mRNA findings, expression of GlcAT-I protein was markedly increased (ϳ2.5-fold; P Ͻ 0.01) in lung fibroblasts after 24 h of treatment with TGF-␤ 1 (Fig. 9C) . TGF-␤ 1 treatment also resulted in increased versican gene expression in normal lung fibroblasts compared with untreated cells (Fig.  9D) . These results indicate that GlcAT-I and versican core protein expression is subject to modulation by TGF-␤ 1 .
TGF-␤ 1 -stimulated GlcAT-I gene expression and CS-GAG production are p38 MAPK-and TGF-␤ type I receptor-/ALK5-dependent.
Having found that TGF-␤ 1 upregulates GlcAT-I gene and protein expression in lung fibroblasts, we examined the signaling pathways that regulate TGF- Fig. 3 . Quantitation of changes in total sulfated glycosaminoglycan (GAG; A) and CS/DS (B) content in normal and fibrotic rat lungs. Frozen dry lung tissues were digested with proteinase K, and the products of proteinase K digests were collected and then digested or not with chondroitinase ABC to determine CS/DS content as described in METHODS. Values are means Ϯ SE of 4 independent observations. One-way ANOVA with post hoc Tukey test was used for statistical analysis of the data. Con, control; d, days.
␤ 1 -induced GlcAT-I expression and CS-GAG production. We first examined whether GlcAT-I induction in TGF-␤ 1 -treated lung fibroblasts would be affected by modulating the p38 MAPK signaling pathway. Fibroblasts were preincubated for 2 h with varying concentrations (0, 10, 20, 25, and 50 M) of SB-203580, a selective inhibitor of p38 MAPK (12), before stimulation with TGF-␤ 1 for 18 h. Strikingly, SB-203580 treatment inhibited TGF-␤ 1 -induced activation of GlcAT-I expression in a concentration-dependent manner. As illustrated in Fig. 10A , inhibition was not seen with a concentration of 10 M, whereas treatment at 20, 25, and 50 M resulted in a marked downregulation of TGF-␤ 1 -induced GlcAT-I expression. To further characterize the signaling pathway involved in TGF-␤ 1 stimulation of GlcAT-I, we examined whether the mRNA levels of GlcAT-I were modulated following pharmacological inhibition of the TGF-␤ type I receptor/ALK5, the principal type I receptor mediating most cellular responses to TGF-␤ (23). Concentration response (0, 10, 20, 25, and 50 M) studies indicated that SB-431542, a small molecule inhibitor of the ALK5 group of TGF-␤ type I receptor (20, 26) , was most effective at inhibiting TGF-␤ 1 -induced GlcAT-I mRNA levels when added at concentrations of 20, 25, and 50 M to lung fibroblasts (Fig. 10B) . Because of a functional link between GlcAT-I expression and formation of CS-GAG . FACE analyses (A) and densitometry quantitation (B-E) of HA and CS/DS in the cell layer fractions of control (saline-instilled lungs; SLF) and fibrotic (BLM-instilled lungs; BLF) rat lung fibroblasts. Disaccharides produced from proteinase K-digested GAGs by hyaluronidase and chondroitinase ABC digestion were fluorotagged and separated by FACE to identify and quantitate ⌬disaccharides. Disaccharides were identified by coelectrophoresis with standards. Densitometry analysis of disaccharides was performed with image analyzer software (see METHODS) . Values are means Ϯ SE of 3 independent observations and expressed in arbitrary densitometry units. Unpaired Student's t-test was used for statistical analysis of the data. ns, Not significant. chains, we next analyzed whether p38 and ALK5 signaling pathways were also important for the TGF-␤-induced CS-GAG production by lung fibroblasts. In TGF-␤ 1 -stimulated cells, secreted CS-GAG chain abundance was twofold higher than in controls. In agreement with the mRNA findings, treatment with SB-203580 (Fig. 10C) or SB-431542 (Fig. 10D ) resulted in a concentration-dependent inhibition in the levels of CS-GAG formation by TGF-␤ 1 -stimulated lung fibroblasts. Together, these results suggest that p38 and ALK5 activation play a key role in TGF-␤ 1 -mediated PG-GAG upregulation.
IPF in humans results in increased deposition and alterations in tissue distribution of CS chains.
To determine whether pulmonary fibrosis results in alterations of tissue distribution and abundance of CS chains, we compared lung sections from IPF patients with that of control subjects. There was an extensive increase in the immunostaining intensity of C-4-S (Fig. 11, B and C) and C-6-S (Fig. 11, E and F) chains in IPF patients, mainly in the area of alveolar injury, fibroblast foci, and alveolar fibrosis. These findings corroborate the observations seen in fibrotic rat lungs (Fig. 1) . In control lungs (Fig. 11, A and D) , staining was restricted to a few weakly staining airway, blood vessel, and alveolar structures.
GlcAT-I protein expression is increased in IPF. Further investigations were undertaken to determine whether GlcAT-I protein expression was also upregulated in IPF patients. Immunostaining for GlcAT-I protein was strongly positive in areas of fibrosis in fibrotic patients (Fig. 11, H and I) , whereas control subjects (Fig. 11G) showed weak staining for GlcAT-I protein. These findings, when considered with our demonstration that GlcAT-I expression significantly increased in areas of fibrosis after BLM instillation to rats, suggest that GlcAT-I plays a role in promoting fibrosis through upregulation of CS-GAG synthesis and deposition.
DISCUSSION
Various methods, including HPLC and capillary zone electrophoresis, are available for analysis of GAG structure; however, these techniques are intricate and require large amounts of biological material. Additionally, these techniques are laborious and normally allow for only one sample to be analyzed at a time. Recent progress in carbohydrate chemistry has facilitated the analysis of the composition and sulfation patterns of GAGs using a novel method called FACE (6) . Although this technique has been described initially for cartilage (5) , recently studies have also adapted this method to analyze GAG structure in lung and other tissues (13, 29) . Notably, separate analysis of hyaluronan, CS/DS, and HS species within a mixed population of GAGs can be achieved using this technique.
The present study demonstrates the utility of FACE, in combination with immunohistochemistry, in identifying disease-related changes in GAG structure in BALF and in the Immunostaining for GlcAT-I protein was strongly positive in areas of fibrosis in fibrotic rat lungs at 14 days after BLM administration (B), whereas control lungs (A) showed weak staining for GlcAT-I protein. The dark brown color is indicative of strong GlcAT-I expression. C is negative control from BLM lungs stained with isotype-matched control antibody. Original magnification, ϫ100. Immunoblotting of GlcAT-I protein in fibrotic rat lungs (D) and fibrotic rat lung fibroblasts (F) is shown. Lung homogenates or cell lysates were prepared, and equal amounts of proteins (50 g/lane) were separated on 10% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were probed with a polyclonal GlcAT-I antibody and then developed by enhanced chemiluminescence assay. Expression of GlcAT-I was quantified by densitometry (E and G) analysis using image analyzer software (see METHODS) . Values are means Ϯ SE of 4 observations and expressed in arbitrary densitometry units. One-way ANOVA with post hoc Tukey test was used for statistical analysis of the data. Expression of GlcAT-I and versican in BLM lung fibrosis is shown. The lung fibroblasts derived from rats 14 days after SLF or BLF instillation were analyzed for expression of GlcAT-I (H) and versican (I) mRNAs by real-time quantitative RT-PCR (QRT-PCR; n ϭ means Ϯ SE of 3 observations). All values were normalized to ribosomal protein S9 mRNA and expressed as relative GlcAT-I-to-S9 or versican-to-S9 mRNA ratios. Unpaired Student's t-test was used for statistical analysis of the data. fibrotic lung. Specifically, changes in disaccharide composition and sulfation of CS chains arise largely during the inflammatory and fibroproliferative phases of BLM-induced lung injury. Activated inflammatory, epithelial, and parenchymal cells produce cytokines and growth factors in response to the BLMinduced injury (30) , and many of these mediators, including TGF-␤ 1 , may influence the inflammatory and fibrogenic process by regulating ECM turnover, including GAGs. Further findings demonstrated increased production of ⌬DiHA, ⌬Di4S, and ⌬Di6S disaccharides by fibroblasts isolated from fibrotic rat lungs compared with normal lung. These results demonstrate that fibroblasts retain the known phenotypic and fibrosisrelated alterations with regard to the expression and disaccharide composition of HA and CS/DS disaccharides. The high levels of HA and CS/DS disaccharides found in fibrotic lungs, and the observation that lung cells, particularly fibroblasts, synthesize and secrete these disaccharides make these molecules a useful marker for disease severity. Although we believe fibroblasts might be the possible source of HA and CS/DS disaccharide, other structural cells such as epithelial cells may also contribute to the GAG pool in lungs (29) . Building on the observations in the BLM animal model of fibrosis, subsequent work in humans demonstrated increased deposition of CSGAGs in patients with IPF compared with normal subjects. In concert, our findings demonstrate that CS/DS side chains undergo significant alterations in composition, sulfation pattern, and distribution, indicating that these GAG chains could have major impact on functional and structural organization of the lung in health and disease.
Although the significance of fibrosis-related changes in the sulfation profile is presently unknown, aberrations in the sulfation of CS/DS chains may be linked to the processes of ECM remodeling during lung injury and repair in pulmonary fibrosis. Increases in sulfation may generate neoepitopes by adding more negative charges and may bestow novel physical and chemical properties to GAG chains. In addition, it is feasible that changes in sulfation pattern of CS/DS GAG chains may result in increased affinity for growth factors, adhesion molecule, or other cytokines that may assist in matrix repair by fibroblasts and/or myofibroblasts. Alterations in expression of GAGs and their sulfation pattern could also affect at least some biologically significant events such as inflammatory cell accumulation, cellular adhesion, migration, and proliferation (19, 21, 22, 28, 36) .
PG composition can be altered through the modulation of biosynthetic pathways, and alterations in lung GAG content can result from stimulation of glycosyltransferases involved in GAG biosynthesis. In this regard, GlcAT-I plays an important role in priming hexuronic acid-containing GAG synthesis but does not participate in the expression of PG core protein. Any   Fig. 9 . TGF-␤1-induces GlcAT-I and versican core protein gene expression. SLF were treated with or without TGF-␤1 (5 ng/ml) for the indicated times, and the cell layers were examined by QRT-PCR for the expression of GlcAT-I (A) and ribosomal protein S9 (housekeeping gene) mRNAs (n ϭ means Ϯ SE of 3 observations). All values were normalized to ribosomal protein S9 mRNA and expressed as relative GlcAT-I-to-S9 mRNA ratio. Expression (B) and quantification (C) of GlcAT-I protein in TGF-␤1-stimulated lung fibroblast culture are shown. Fibroblasts were treated with or without TGF-␤1 (5 ng/ml; SLFϩTGF-␤1) for 24 h, and cell lysates were prepared. Equal amounts of proteins were separated on 10% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were probed with a polyclonal GlcAT-I antibody and then developed by enhanced chemiluminescence assay. Expression of GlcAT-I was quantified by densitometry analysis using image analyzer software (see METHODS) . Values are means Ϯ SE of 3 independent observations in duplicate and expressed in arbitrary densitometry units. One-way ANOVA with post hoc Tukey test was used for statistical analysis of GlcAT-I mRNA measurement, whereas paired Student's t-test was used for statistical analysis of the GlcAT-I protein. D: TGF-␤1-induced versican mRNA expression in lung fibroblasts. SLF were treated with or without TGF-␤1 (5 ng/ml) for 18 h, and the cell layers were examined by QRT-PCR for the expression of versican and ribosomal protein S9 mRNAs (n ϭ means Ϯ SE of 3 observations). All values were normalized to ribosomal protein S9 mRNA and expressed as relative versican-to-S9 mRNA ratio. Paired Student's t-test was used for statistical analysis of the versican expression. alteration in GlcAT-I expression could be expected to influence the rate of synthesis and deposition of GAG chains (3, 16, 42) and therefore PG structure and properties. Accordingly, GlcAT-I protein immunoreactivity was strongly increased in surgical specimens from pulmonary fibrosis patients as well as in fibrotic rat lungs compared with control groups. Immunoblot results from fibrotic rat lungs confirmed the higher expression of GlcAT-I protein in diseased lungs.
To further explore the mechanistic aspects of PG core protein and GAG regulation, we studied expression of GlcAT-I and versican core protein mRNAs and CS-GAG production in primary cultures of SLF or BLF. In agreement with our in vivo data, GlcAT-I gene expression and CS-GAG production were higher in BLF than SLF, indicating alterations in the expression of GlcAT-I are consistent between fibrotic lungs and fibrotic lung fibroblasts in in vitro cultures. Results also showed that versican core protein gene expression was significantly higher in BLF than SLF. The increase in versican mRNA levels in the present study matches our earlier demonstration of increased secretion of versican core protein by fibrotic lung fibroblasts (44) . Studies have indicated that there are four versican isoforms (V0, V1, V2, and V3), which include different combinations of two GAG-binding domains, termed GAG-␣ and GAG-␤, due to differential splicing of exons 7 and 8. In this study, we analyzed the expression of V0 isoform, which has both GAG-␣ and GAG-␤ domains. Spontaneous higher expression of GlcAT-I and CS-GAGs by primary cultures of BLF was observed in the absence of exogenous stimulation, indicating these fibroblasts may maintain the phenotype that occurs in vivo.
Our present study also demonstrates that TGF-␤ 1 -stimulated primary rat lung fibroblasts upregulated GlcAT-I mRNA and protein expression. As a consequence of GlcAT-I induction, levels of the CS-GAG chains were increased in TGF-␤ 1 -treated fibroblast cultures, whereas treatment of fibroblast cultures with a neutralizing antibody to TGF-␤ 1 showed reductions in the level of GAGs. The observed reduction in HA and CS/DS not only in fibrotic lung fibroblasts, but also in normal fibroblasts, by anti-TGF-␤ 1 treatment suggests that TGF-␤ 1 might be important in regulating HA and CS/DS GAGs in normal steady state as well as in fibrotic conditions. However, the effects of TGF-␤ 1 on HA and CS/DS may depend on the independent regulation of hyaluronan and CS/DS synthesizing enzymes hyaluronan synthases and glycosyltransferases, re- After treatment, medium was collected and centrifuged, and supernatants were assayed for GAG content. Total RNA was isolated from cell layers and reverse-transcribed. QRT-PCR was performed on the cDNA for the expression of the housekeeping gene ribosomal protein S9 and GlcAT-I mRNA. Relative expression of GlcAT-I mRNA was normalized to ribosomal protein S9 expression and expressed as relative GlcAT-I-to-S9 mRNA ratio. Treatment with TGF-␤1 induced GlcAT-I gene upregulation and CS-GAG content, whereas SB-203580 and SB-431542 inhibited the GlcAT-I mRNA and levels of CS-GAG in a dose-dependent manner. Data are expressed means Ϯ SE of 3 observations, and 1-way ANOVA with post hoc Tukey test was used for statistical analysis of the data.
spectively. TGF-␤ 1 has been shown to be a regulator of hyaluronan synthase expression in vascular endothelial cells and synovial fibroblasts in vitro (39, 40) as well as GlcAT-I expression in nucleus pulposus cells (18) . Future studies are needed to investigate the transcriptional regulatory mechanisms that mediate expression of PG-GAGs in these fibroblasts. It is interesting to note that TGF-␤ 1 induced a parallel response in the rat lung fibroblasts to upregulate versican mRNA expression. These are interesting and novel observations given the fact that PG synthesis is correlated with levels of versican core protein and GlcAT-I mRNAs, since versican core protein is the substrate for CS-GAG chain attachment, and GlcAT-I is the rate-limiting enzyme for CS-GAG chain synthesis. These findings also demonstrate for the first time that TGF-␤ 1 influences both versican core protein and GlcAT-I gene expression in concert to regulate lung fibroblast PG production. Upregulation of the expression of versican core protein and CS by TGF-␤ 1 may be mediated independently by controlling relevant enzymes or factors in the biosynthetic pathway of GAGs and core protein.
In light of these data, we next investigated the signaling pathways underlying TGF-␤ 1 -induced GlcAT-I expression and CS-GAG production in lung fibroblasts. TGF-␤ signaling (27, 31) initiates when the TGF-␤ ligand binds to the TGF-␤ type II receptor (TGF-␤RII), with subsequent recruitment of its type I receptor, ALK5. Phosphorylation of the type I receptor by the type II receptor activates Smad transcription factors resulting in Smad2 and Smad3 phosphorylation. Phosphorylated Smad2 and Smad3 form heterodimeric and heterotrimeric complexes with Smad4 that accumulate in the nucleus and control expression of target genes in a manner specific to type I receptor and cell type. In addition, TGF-␤ also activates non-Smad pathways, including the p38 MAPK pathway (23) . We have presented evidence for the first time that pharmacological inhibition of TGF-␤ type I receptor/ALK5 with SB-431542 or p38 MAPK with SB-203580 strongly blocked the TGF-␤ 1 stimu- Fig. 11 . Photomicrographs of lung sections from idiopathic pulmonary fibrosis (IPF) patients and control subjects showing immunostaining for C-4-S (A-C), C-6-S (D-F), and GlcAT-I (G-I). Immunostaining for C-4-S, C-6-S, and GlcAT-I was faint in control lungs (A, D, and G, respectively) but intense in IPF lungs (B, E, and H, respectively). The insets in B, E, and H are shown magnified in C, F, and I, respectively. The dark red color is indicative of excess deposition of CS-GAGs and strong GlcAT-I expression. The black arrows show the site of CS-GAG deposition (C and F) or localization of GlcAT-I protein (I). Photos are representative images of 3 IPF patients and 3 control subjects. Original magnification, ϫ40 (A, B, D , E, G, and H) or ϫ200 (C, F, and I).
lation of GlcAT-I mRNA, concomitant with CS-GAG production, in a concentration-dependent manner. Blockade of p38 MAPK and ALK5 was shown previously to inhibit PG synthesis in vascular smooth muscle cells (8) and cardiac fibroblasts (33) . Collectively, these results provide an opportunity to test the use of small molecule inhibitors for inhibiting excessive PG deposition in pulmonary fibrosis.
The current knowledge about the mechanism of increased expression of GAGs in pulmonary fibrosis is limited. Given the fact that GlcAT-I is a key enzyme-regulating biosynthesis of CS-GAG chains, upregulation of GlcAT-I provides a novel mechanism by which GAG synthesis is increased in fibrosis. Although the precise molecular mechanisms involved require further elaboration, our studies provide a working basis for further studies of the effect of GlcAT-I on GAG synthesis. A better understanding of changes in expression, disaccharide composition, and sulfation patterns of GAGs during tissue injury, inflammation, and repair may be helpful in designing targeted therapies for inhibition of pulmonary fibrosis.
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